continuingmedicaleducation

In this podcast series, expert clinicians will discuss patient wellness and its importance for rheumatology providers. Key components of wellness such as diet, exercise, and sleep will be discussed. Listen in as Drs. Len Calabrese and Elaine Husni discuss why wellness is important for patients with rheumatic diseases.

For CME Credit, complete activity here: https://tinyurl.com/Rheumatology1

In this podcast, expert clinicians review strategies to engage patients with hemophilia A in their own care to improve overall patient satisfaction.

In this podcast, a clinician and patient discuss his experience with hemophilia A, addressing patient concerns regarding this condition, its management, and preferred communication methods. 

In this podcast, expert clinicians discuss recent and emerging treatment options with the potential to benefit patients with and without inhibitors.

In this podcast, expert clinicians discuss historical challenges in hemophilia A care and how recent therapeutic advancements help to overcome these limitations. 

In this podcast, expert clinicians will discuss treatment for a patient with refractory Mycobacterium avium complex lung disease despite many months of guidelines-based therapy. 

For CME Credit, complete activity here: https://tinyurl.com/LungMET2

In this podcast, expert clinicians will discuss treatment for Mycobacterium avium complex lung infection in a patient with underlying granulomatosis with polyangiitis affecting the lungs. 

For CME Credit, complete activity here:

https://tinyurl.com/LungMET1

In this 4-part CME podcast series, experts will review the clinical aspects and primary risk factors for HZ, discuss optimized use of vaccines for at-risk populations, and provide guidance on effective patient education strategies to enhance vaccine uptake. In this episode, Drs. Len Calabrese and Cassandra Calabrese review zoster vaccine side effects and patient education strategies to enhance vaccination rates.

For CME Credit, complete activity here: https://tinyurl.com/HZ004 

In this 4-part CME podcast series, experts will review the clinical aspects and primary risk factors for HZ, discuss optimized use of vaccines for at-risk populations, and provide guidance on effective patient education strategies to enhance vaccine uptake. In this episode, Drs. Calabrese and Sax review zoster vaccine safety and efficacy and discuss strategies for vaccination. 

For CME Credit, complete activity here: https://tinyurl.com/HerpZo3 

In this 4-part CME podcast series, experts will review the clinical aspects and primary risk factors for HZ, discuss optimized use of vaccines for at-risk populations, and provide guidance on effective patient education strategies to enhance vaccine uptake. In this episode, Drs. Calabrese and Curtis discuss primary risk factors for HZ, incidence rates among patients with IMID, and optimized use of vaccines for these at-risk populations.

For CME Credit, complete activity here: https://tinyurl.com/HZ002 

In this 4-part CME podcast series, experts will review the clinical aspects and primary risk factors for HZ, discuss optimized use of vaccines for at-risk populations, and provide guidance on effective patient education strategies to enhance vaccine uptake. In this episode, Drs. Len Calabrese and Cassandra Calabrese discuss the clinical manifestations of herpes zoster and potential sequelae.

For CME Credit, complete activity here: https://tinyurl.com/HZ001 

Interstitial lung disease (ILD) describes a group of over more than 200 rare pulmonary conditions characterized by fibrosis of the lung. ILD can have several causes, including environmental antigens, bacterial, viral, and fungal infections, gastroesophageal reflux, occupational hazards (eg, asbestos), or a connective tissue disease (CTD). Patients with systemic sclerosis (SSc), rheumatoid arthritis (RA), or poly-/dermatomyositis (PM/DM), have the greatest risk of developing CTD-associated ILD. Idiopathic pulmonary fibrosis (IPF) is the most common ILD, though patients who develop a progressive-fibrosing phenotype ILD (PF-ILD) are subject to similar outcomes. With historically limited treatment options, pulmonologists, rheumatologists, radiologists, and other providers who care for patients with PF-ILD are unaware of how new options and data for patients with IPF may benefit patients with PF-ILD. In this educational activity, expert clinicians will discuss a challenging case on treating a patient with PF-ILD.

Transcript: https://tinyurl.com/PF-ILD4Transcript

For CME Credit, complete activity here: https://tinyurl.com/PF-ILD4

Interstitial lung disease (ILD) describes a group of over more than 200 rare pulmonary conditions characterized by fibrosis of the lung. ILD can have several causes, including environmental antigens, bacterial, viral, and fungal infections, gastroesophageal reflux, occupational hazards (eg, asbestos), or a connective tissue disease (CTD). Patients with systemic sclerosis (SSc), rheumatoid arthritis (RA), or poly-/dermatomyositis (PM/DM), have the greatest risk of developing CTD-associated ILD. Idiopathic pulmonary fibrosis (IPF) is the most common ILD, though patients who develop a progressive-fibrosing phenotype ILD (PF-ILD) are subject to similar outcomes. With historically limited treatment options, pulmonologists, rheumatologists, radiologists, and other providers who care for patients with PF-ILD are unaware of how new options and data for patients with IPF may benefit patients with PF-ILD. In this educational activity, expert clinicians will discuss a challenging case on diagnosing a patient with PF-ILD.

Transcript: https://tinyurl.com/PF-ILD3Transcript

For CME Credit, complete activity here: https://tinyurl.com/PF-ILD3

Interstitial lung disease (ILD) describes a group of over more than 200 rare pulmonary conditions characterized by fibrosis of the lung. ILD can have several causes, including environmental antigens, bacterial, viral, and fungal infections, gastroesophageal reflux, occupational hazards (eg, asbestos), or a connective tissue disease (CTD). Patients with systemic sclerosis (SSc), rheumatoid arthritis (RA), or poly-/dermatomyositis (PM/DM), have the greatest risk of developing CTD-associated ILD. Idiopathic pulmonary fibrosis (IPF) is the most common ILD, though patients who develop a progressive-fibrosing phenotype ILD (PF-ILD) are subject to similar outcomes. With historically limited treatment options, pulmonologists, rheumatologists, radiologists, and other providers who care for patients with PF-ILD are unaware of how new options and data for patients with IPF may benefit patients with PF-ILD. In this educational activity, expert clinicians will discuss a challenging case on treating a patient with PF-ILD.

Transcript: https://tinyurl.com/PF-ILD2Transcript

For CME Credit, complete activity here: https://tinyurl.com/PF-ILD2

Interstitial lung disease (ILD) describes a group of over more than 200 rare pulmonary conditions characterized by fibrosis of the lung. ILD can have several causes, including environmental antigens, bacterial, viral, and fungal infections, gastroesophageal reflux, occupational hazards (eg, asbestos), or a connective tissue disease (CTD). Patients with systemic sclerosis (SSc), rheumatoid arthritis (RA), or poly-/dermatomyositis (PM/DM), have the greatest risk of developing CTD-associated ILD. Idiopathic pulmonary fibrosis (IPF) is the most common ILD, though patients who develop a progressive-fibrosing phenotype ILD (PF-ILD) are subject to similar outcomes. With historically limited treatment options, pulmonologists, rheumatologists, radiologists, and other providers who care for patients with PF-ILD are unaware of how new options and data for patients with IPF may benefit patients with PF-ILD. In this educational activity, expert clinicians will discuss a challenging case on diagnosing a patient with PF-ILD.

Transcript: https://tinyurl.com/PF-ILD1Transcript

For CME Credit, complete activity here: https://tinyurl.com/PF-ILD1

The intended audience for this series is pulmonologists, internists, rheumatologists and other health care professionals involved in the management of patients with progressive fibrosing interstitial lung disease (PF-ILD).

In this podcast, expert clinicians will discuss the burden of tardive dyskinesia (TD) on the patient and health care system. TD is a neurological disorder characterized by persistent involuntary movements that can be debilitating. It is commonly associated with exposure to dopamine receptor antagonists, including both typical and atypical antipsychotics. TD is associated with a high health care burden, but outcomes can be optimized through coordinated care efforts. Recently, the US Food and Drug Administration approved new treatments for patients with TD. Most providers are unfamiliar with these novel therapies and the discrepancies in their use. The other episodes in this series will cover the symptoms, pathology, and causes of TD, as well as available therapies, and multidisciplinary care approaches to consider.

Transcript: https://tinyurl.com/PrimaryCare3-2

For CME Credit, complete activity here: https://tinyurl.com/PrimaryCare3-2a

In this podcast, expert clinicians will discuss the symptoms, pathology, and causes of tardive dyskinesia (TD). TD is a neurological disorder characterized by persistent involuntary movements that can be debilitating. It is commonly associated with exposure to dopamine receptor antagonists, including both typical and atypical antipsychotics. TD is associated with a high health care burden, but outcomes can be optimized through coordinated care efforts. Recently, the US Food and Drug Administration approved new treatments for patients with TD. Most providers are unfamiliar with these novel therapies and the discrepancies in their use. The other episodes in this series will cover the burden of TD, as well as available therapies, and multidisciplinary care approaches to consider.

Transcript: https://tinyurl.com/PrimaryCare3-1

For CME Credit, complete activity here: https://tinyurl.com/PrimaryCare3-1a

While the impact of influenza varies, it places a substantial burden on the health of people in the United States each year. The Centers for Disease Control and Prevention (CDC) estimates that influenza has resulted in between 9.2 million and 35.6 million illnesses, between 140,000 and 710,000 hospitalizations, and between 12,000 and 56,000 deaths annually since 2010. There is a need for better treatments for patients with influenza infection, preventative measures, and better mitigation for the impact associated with a pandemic. Antivirals with different targets and different mechanisms of action provide multiple therapeutic options and hold promise in improving treatment effectiveness, especially in pediatric and adolescent patients. In this podcast series, expert clinicians will discuss the latest evidence regarding the use of antiviral agents for the treatment of patients with influenza who are at normal or high risk for complications and the use of antiviral agents for influenza treatment based on their efficacy and ability to reduce the transmission of the disease.

For CME Credit, click here: https://tinyurl.com/pediatricss1e3

While the impact of influenza varies, it places a substantial burden on the health of people in the United States each year. The Centers for Disease Control and Prevention (CDC) estimates that influenza has resulted in between 9.2 million and 35.6 million illnesses, between 140,000 and 710,000 hospitalizations, and between 12,000 and 56,000 deaths annually since 2010. There is a need for better treatments for patients with influenza infection, preventative measures, and better mitigation for the impact associated with a pandemic. Antivirals with different targets and different mechanisms of action provide multiple therapeutic options and hold promise in improving treatment effectiveness, especially in pediatric and adolescent patients. In this podcast series, expert clinicians will discuss the latest evidence regarding the use of antiviral agents for the treatment of patients with influenza who are at normal or high risk for complications and the use of antiviral agents for influenza treatment based on their efficacy and ability to reduce the transmission of the disease.

For CME Credit, complete activity here: https://tinyurl.com/pediatricss1e1